

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-2 (canceled).

Claim 3 (currently amended): A compound of Claim 4 16 wherein said compound has the (R, R) stereo configuration.

Claims 4 (withdrawn): A method for increasing the level of endogenous growth hormone in a human or an animal which comprises administering to said human or an animal which comprises administering to said human or animal an effective amount of a compound of Claim 1.

Claim 5 (withdrawn): A method for the treatment or prevention of a physiological condition which may be modulated by an increase in endogenous growth hormone which comprises administering to an animal in need of said treatment an effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt or solvate thereof.

Claim 6 (currently amended): A pharmaceutical formulation which comprises, as an active ingredient a compound of Claim 4 16, or a pharmaceutically acceptable salt or solvate thereof, associated with one or more pharmaceutically acceptable carriers, diluents, or excipients.

Claim 7 (withdrawn): A pharmaceutical formulation according to Claim 6 which further comprises a bone-antiresorptive agent.

Claim 8 (withdrawn): A method according to Claim 5 which further comprises administering to a patient a bone-antiresorptive agent.

Claim 9 (withdrawn): A method according to Claim 8 wherein said bone-antiresorptive agent is a bisphosphonate.


Claims 10-12 (canceled).

Claim 13 (currently amended): A pharmaceutical formulation which comprises, as an active ingredient a compound of Claim ~~10~~ 17, or a pharmaceutically acceptable salt or solvate thereof, associated with one or more pharmaceutically acceptable carriers, diluents, or excipients.

Claim 14 (withdrawn): A pharmaceutical formulation according to Claim 13 which further comprises a bone-antiresorptive agent.


Claim 15 (withdrawn): A method for the treatment or prevention of a physiological condition which may be modulated by an increase in endogenous growth hormone which comprises administering to an animal in need of said treatment an effective amount of a compound of Claim 10 or a pharmaceutically acceptable salt or solvate thereof.

Claim 16 (new): A compound selected from the group consisting of the following structurally depicted compounds:




or a pharmaceutically acceptable salt or solvate thereof.

Claim 17 (new). A compound according to Claim 16 having the formula




or a pharmaceutically acceptable salt or solvate thereof.

Claim 18 (new). A compound according to Claim 16 having the formula



or a pharmaceutically acceptable salt or solvate thereof.

Claim 19 (new). A compound according to Claim 16 having the formula



; or a pharmaceutically acceptable salt or solvate thereof.

Claim 20 (new). A compound of Claim 17 wherein said compound has the (R, R) stereo configuration.

Claim 21 (new). A compound of Claim 18 wherein said compound has the (R, R) stereo configuration.

Claim 22 (new). A compound of Claim 19 wherein said compound has the (R, R) stereo configuration.

Claim 22 (new). A pharmaceutical formulation which comprises, as an active ingredient a compound of Claim 18, or a pharmaceutically acceptable salt or solvate thereof, associated with one or more pharmaceutically acceptable carriers, diluents, or excipients.

Claim 24 (new). A pharmaceutical formulation which comprises, as an active ingredient a compound of Claim 19, or a pharmaceutically acceptable salt or solvate thereof, associated with one or more pharmaceutically acceptable carriers, diluents, or excipients.